Table 4.
TFs with enriched TFBSs in CRMs where Hb or Kr are activators or repressors.
| TF | Hb | Kr | ||
|---|---|---|---|---|
| p-value for set | p-value for set | |||
| act | rep | act | rep | |
| # of CRMs | 17 | 27 | 11 | 33 |
| Abd-B | 0.0 | 0.0 | 0.0 | 0.0 |
| Deaf1 | 0.079 | 0.005 | ||
| His2B | 0.048 | 0.0 | 0.0 | 0.058 |
| Hsf* | 0.085 | 0.008 | 0.0 | 0.231 |
| Kr | 0.0 | 0.0 | 0.0 | 0.0 |
| Bcd | 0.0 | 0.0 | 0.0 | 0.0 |
| Br-Z4+ | 0.821 | 0.006 | ||
| Cad | 0.002 | 0.0 | 0.0 | 0.0 |
| Hb | 0.032 | 0.0 | 0.0 | 0.0 |
| Kni | 0.032 | 0.01 | 0.702 | 0.0 |
| Tll | 0.003 | 0.0 | 0.0 | 0.0 |
| Ttk | 0.02 | 0.0 | 0.003 | 0.0 |
The first row shows the number of CRMs in each set. Each following row shows a TF out of the 76 tested for which a Clover [19] analysis resulted in a significant over- or under-representation in the sequences where Hb is preferred as activator (second column) or repressor (third column) or Kr preferred as activator (fourth column) or repressor (fifth column), respectively. Highlighted in bold are the cases with differential enrichment between the activator and repressor set. The TF marked with "*" is not expressed during the developmental time points C13 and C14 as determined from in-situ staining images http://www.flyexpress.net. The TF marked with "+" has a binding profile that is very similar to Bcd. Empty cells indicate that the TF was not significant for the sequence sets of Hb.